The purported recovery from AD in a mouse model with the addition of a retinoid X receptor agonist, bexarotene, that overproduced Apolipoprotein E (ApoE) and led to the eventual removal of Aβ from the brain, demonstrated that effective downstream clearance could be critical for the reversal of AD in a mouse. This evidence concerns the gene APOE and Alzheimer disease.